Abstract
The clinical benefits of the MammaPrint® signature for breast cancer is well documented; however, how these genes are related to cell cycle perturbation have not been well determined. Our single-cell transcriptome mapping (algorithm) provides details into the fine perturbation of all individual genes during a cell cycle, providing a view of the cell-cycle-phase specific landscape of any given human genes. Specifically, we identified that 38 out of the 70 (54%) MammaPrint® signature genes are perturbated to a specific phase of the cell cycle. The MammaPrint® signature panel derived its clinical prognosis power from measuring the cell cycle activity of specific breast cancer samples. Such cell cycle phase index of the MammaPrint® signature suggested that measurement of the cell cycle index from tumors could be developed into a prognosis tool for various types of cancer beyond breast cancer, potentially improving therapy through targeting a specific phase of the cell cycle of cancer cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 33290-33301 |
| Number of pages | 12 |
| Journal | Oncotarget |
| Volume | 9 |
| Issue number | 70 |
| DOIs | |
| State | Published - Sep 1 2018 |
Funding
We thank Meng Li (USC Bioinformatics Core Facility) for bioinformatic analysis, and Dr. Bridget Samuels (PhD, Caltech) for editing the manuscript. This work was supported in part by the National Institutes of Health (NCI, R01CA164509; NIEHS, R01ES021801-04S1) and by CHOC Children's Foundation, CHOC-UCI Joint Research Awards (2014, 2015, 2016).
Keywords
- Cell cycle
- Cell cycle phase
- Cell-cycle-staged therapy
- Single-cell
- Transcriptome
ASJC Scopus subject areas
- Oncology
